Diabetic amyotrophy diagnosis marker and application thereof
Through the detection of IGFBP3 protein, the problem of lack of diagnostic markers for diabetic myotrophy was solved, and a diagnosis and screening system for diabetic myotrophy was developed, which realized early detection and monitoring of diabetic myotrophy, and improved the level of clinical diagnosis and treatment evaluation. .
Patent Information
- Application Number
- CN202411091853.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-09
- Publication Date
- 2024-11-22
AI Technical Summary
At present, the pathogenesis and diagnostic markers of diabetic myotrophy are severely lacking, which leads to severe challenges in the treatment and rehabilitation of diabetic patients, especially the lack of effective means for diagnosis and monitoring of middle-aged and elderly patients.
Using IGFBP3 protein as a clinical diagnostic marker for diabetic muscular atrophy, by detecting the content of IGFBP3 protein in the blood, develop kits and systems for diagnosis and screening, and use antibodies, proteins and/or polypeptides that specifically detect IGFBP3 protein, Combined with isotopes, horseradish peroxidase, colloidal gold, fluorescent probes and other modifications, early detection and monitoring of diabetic muscular atrophy.
Through the detection of IGFBP3 protein, it can significantly distinguish between diabetic and normal people. The content is highly correlated with muscle mass, providing a method to monitor the progress of diabetic and myocardial atrophy disease in real time, and improving the level of clinical diagnosis, treatment and prognosis evaluation.
Smart Images

Figure HDA0004986803850000011 
Figure HDA0004986803850000012 
Figure HDA0004986803850000021
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine technology, and in particular relates to a diabetic amyotrophy diagnostic marker and application thereof. Background Art
[0002] Diabetes is a major chronic disease that is well known to everyone. Among the many complications, muscle diseases represented by muscle atrophy are important complications that are often overlooked in clinical practice. The accelerated decline of muscle function leads to a sharp increase in the risk of disability and death, making the treatment and rehabilitation of diabetic patients face more severe challenges. In the past 50 years, with the continuous aging of the population, nearly half of diabetic patients are elderly people over the age of 65, causing a sharp increase in the risk of accidents for middle-aged and elderly diabetic patients. Unfortunately, there is a serious lack of knowledge about the pathogenesis and diagnostic markers of diabetic muscle atrophy, and in-depth and breakthrough basic research is urgent. Summary of the invention
[0003] In order to overcome the defects of the above-mentioned prior art, the purpose of the present invention is to provide a diagnostic marker for diabetic muscle atrophy and its application. IGFBP3 is used as a clinical diagnostic marker for diabetic muscle atrophy. The content of this marker has significant differences between diabetic people and normal healthy people. At the same time, the content of this marker is highly correlated with the body's muscle content.
[0004] In order to achieve the above object, the technical solution of the present invention is:
[0005] A diagnostic marker for diabetic amyotrophy, wherein the marker is IGFBP3 protein, and the IGFBP3 protein is the total IGFBP3 protein in free or bound form in human blood.
[0006] An application of a diagnostic marker for diabetic muscular atrophy, wherein IGFBP3 protein is used as a biomarker for diagnosing diabetic muscular atrophy.
[0007] An application of a diabetic amyotrophy diagnostic marker, a substance for detecting the content of IGFBP3 protein in blood, in diagnosing or assisting in diagnosing whether a person to be tested suffers from diabetic amyotrophy;
[0008] A substance for detecting the IGFBP3 protein content in blood is used in screening or assisting in screening whether a person to be tested suffers from diabetic muscular atrophy.
[0009] Use of a substance for detecting the content of IGFBP3 protein in blood in the preparation of a product for diagnosing or assisting in diagnosing whether a person to be tested suffers from diabetic muscular atrophy;
[0010] A substance for detecting the IGFBP3 protein content in blood is used in the preparation of a product for screening or assisting in screening whether a person to be tested suffers from diabetic muscular atrophy.
[0011] An application of a diabetic amyotrophy diagnostic marker, wherein blood IGFBP3 protein is used as a marker in diagnosing or assisting in diagnosing whether a person to be tested suffers from diabetic amyotrophy;
[0012] Use of blood IGFBP3 protein as a marker in screening or assisting in screening whether a person to be tested suffers from diabetic amyotrophy;
[0013] The candidate human being to be tested is a diabetic patient, a suspected diabetic patient, a diabetic high-risk person, or a direct relative of a diabetic patient.
[0014] An application of a diabetic muscle atrophy diagnostic marker to prepare a product for diagnosing or assisting in diagnosis, screening or assisting in screening whether a person to be tested suffers from diabetic muscle atrophy. The product diagnoses or assists in diagnosis, screening or assists in screening whether a person to be tested suffers from diabetic muscle atrophy based on the protein content of IGFBP3 in a blood sample.
[0015] The product is a kit; the kit comprises a reagent for specifically detecting the level of IGFBP3 protein; the reagent comprises an antibody, protein and / or polypeptide that specifically binds to the IGFBP3 protein.
[0016] The antibodies, proteins and / or polypeptides are modified with isotopes, horseradish peroxidase, colloidal gold, fluorescent probes, etc., or are unmodified.
[0017] An application of a diabetic amyotrophy diagnostic marker provides a system for diagnosing or assisting in diagnosis, screening or assisting in screening whether a person to be tested has diabetes based on the marker IGFBP3 protein, including:
[0018] An acquisition device is used to obtain the IGFBP3 protein content in a biological sample; the biological sample comes from the blood of a person to be tested;
[0019] The judging device is connected to or wirelessly connected to the obtaining device, and is used for diagnosing or assisting in diagnosis, screening or assisting in screening whether the person to be tested suffers from diabetic amyotrophy based on the IGFBP3 protein content in the biological sample.
[0020] The IGFBP3 protein content in the biological sample is higher than that in a normal sample, which indicates that the biological sample suffers from diabetic amyotrophy; the biological sample is blood from a person to be tested.
[0021] Compared with the prior art, the present invention has the following beneficial technical effects:
[0022] 1. Through the creative work of the inventors, the present invention uses normal people and diabetic people to complete physical analysis and blood sample analysis, and finds IGFBP3 protein as a marker of diabetic muscle atrophy. The content of this marker in diabetic people and normal healthy people has significant differences. The IGFBP3 content of male and female diabetic people is higher than that of normal healthy people. At the same time, the content of this marker is highly correlated with the muscle content of the body, and the increase of the marker content is significantly correlated with the decrease of muscle mass in diabetic people.
[0023] 2. The marker can be used to prepare detection and screening kits or systems for muscle atrophy in diabetic patients, which can monitor the disease progression of diabetic muscle atrophy in real time and improve the level of clinical diagnosis and prognosis assessment. BRIEF DESCRIPTION OF THE DRAWINGS
[0024] Figure 1 This is a blood biochemical analysis chart. Figure 1 (A) Blood biochemical analysis shows that the fasting blood glucose level of diabetic patients is significantly higher than that of normal people, regardless of gender; Figure 1 (B) Blood biochemical analysis showed that there was no significant difference in serum high-density lipoprotein cholesterol levels between diabetic and normal subjects, regardless of gender; Figure 1 (C) Blood biochemical analysis showed that there was no significant difference in serum low-density lipoprotein cholesterol levels between diabetic and normal subjects, regardless of gender; Figure 1 (D) Blood biochemical analysis showed that there was no significant difference in serum triglyceride (TG) levels between diabetic and normal people, regardless of gender.
[0025] Figure 2 It is a muscle index correction analysis display chart using different indicators. Figure 2 (A) is corrected for muscle index by height squared (ASM / height 2 ) Schematic diagram of analysis results;
[0026] Figure 2 (B) Schematic diagram of the analysis results of muscle index correction (ASM / BMI) by BMI (weight / squared height); Figure 2 (C) Schematic diagram of the analysis results of muscle index correction by body weight (ASM / body weight).
[0027] Figure 3 This is a schematic diagram of the results of serum IGFBP3 protein content in diabetic patients.
[0028] Figure 4 This is a schematic diagram showing that the serum IGFBP3 protein content is significantly negatively correlated with the body's muscle mass. Figure 4(A) Serum IGFBP3 content and height square corrected muscle index (ASM / height 2 ) is a schematic diagram of the results of association analysis; Figure 4 (B) Schematic diagram of the correlation analysis results between serum IGFBP3 content and BMI-corrected muscle index (ASM / BMI); Figure 4 (C) Schematic diagram of the correlation analysis results between serum IGFBP3 content and body weight-corrected muscle index (ASM / body weight). DETAILED DESCRIPTION
[0029] The present invention is further described in detail below in conjunction with specific embodiments, which are intended to explain the present invention rather than to limit it.
[0030] The experimental means and experimental operations required for the present invention are provided below.
[0031] 1. Population recruitment and inclusion criteria
[0032] All subjects signed an informed consent before joining the study. A total of 333 participants, including diabetic patients and age-matched healthy controls, were recruited between 2021 and 2023. According to China's "Guidelines for the Prevention and Treatment of Type 2 Diabetes (2020 Edition)", diabetes is defined as glycated hemoglobin (HbA1c) ≥ 6.5%, fasting blood glucose (FBG) ≥ 7.0 mmol / L, or 2-hour oral glucose tolerance test (OGTT) ≥ 11.1 mmol / L.
[0033] 2. Body composition analysis
[0034] For body composition analysis, all participants were evaluated using a body composition analyzer (DBA-510, Beijing Donghuayuan Medical Instrument Co., Ltd.). Before the test, participants were asked to avoid any additional physical activity. Each participant held the hand electrodes as instructed and was measured according to the manufacturer's standard procedures. The collected data included protein mass, muscle mass, lean body mass, minerals, etc. for further analysis.
[0035] 3. Blood biochemical analysis
[0036] For blood analysis, all participants were asked to fast overnight. Blood samples were collected by trained doctors. Serum triglycerides (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and glucose were analyzed using Beckman AU5800 biochemical analyzer (California, USA).
[0037] 4. Serum Separation
[0038] During the blood collection process, some blood samples are stored in vacuum serum separation tubes. After blood collection, gently invert the tubes 5-10 times to ensure that the blood is fully mixed with the gel or coagulant. Let the collected blood sample tubes stand (at room temperature) for 30 minutes to 1 hour to allow the blood to coagulate naturally. Avoid shaking or violently moving the tubes. Place the coagulated blood sample in a centrifuge at 3000rpm (relative centrifugal force is approximately 1000-1500×g) for 10-15 minutes. After centrifugation, carefully remove the tubes and use a pipette to carefully transfer the clear serum on the upper layer to a labeled sterile tube. Store it in a -80℃ refrigerator for subsequent analysis.
[0039] 5. ELISA analysis of IGFBP3 content
[0040] IGFBP3 antibody was coated in a 96-well plate. 50ul of standard or fresh serum specimen was added to the coated 96-well microplate, and incubated at 37℃ for 1 hour. The concentration gradient of standard was 0, 1, 5, 10, 50, 100, 300, 500ng / ml. IGFBP3 was bound to the antibody connected to the solid phase carrier. Then 100ul of biotinylated IGFBP3 antibody solution was added and incubated at 37℃ for 1 hour. The unbound biotinylated antibody was washed 3 times with buffer, 100ul of HRP-labeled avidin solution was added, incubated at 37℃ for 30 minutes, washed again 5 times, and 90ul of TMB substrate was added for color development. Incubated at 37℃ for 15 minutes, 50μL of stop solution was added, and the reading was immediately at 450nm. TMB was converted into blue under the catalysis of peroxidase, and converted into the final yellow under the action of acid. The depth of color was positively correlated with the IGFBP3 in the sample. The absorbance (OD value) was measured at a wavelength of 450 nm using an enzyme reader to calculate the sample concentration.
[0041] 6. Statistical Analysis
[0042] Data are presented as mean ± SEM. Data were analyzed using Prism (GraphPad). Pairwise comparisons were performed using a two-tailed Student's T test. Correlation analysis was performed using a univariate linear regression model. p < 0.05 was considered significant.
[0043] The relevant results of the experiments of the present invention are given below.
[0044] 1. Diabetic people have high blood sugar and normal blood lipids
[0045] The typical clinical feature of diabetes is high blood sugar. The population recruited and screened in this study was classified according to the clinical diagnostic criteria. It can be seen that the fasting blood sugar of the diabetic population, both male and female, is significantly higher than that of the normal population. Blood lipid analysis showed that there was no significant difference in the levels of high-density lipoprotein cholesterol, low-density lipoprotein cholesterol and triglycerides between the diabetic population and the normal population, indicating that the clinical indications of the diabetic population were relatively concentrated, and there were no complications of diabetes such as high blood lipids. Figure 1 As shown, 333 normal people and clinically diagnosed diabetic people were recruited from the society, including 166 males including 92 healthy people and 74 diabetic patients, and 167 females including 79 healthy people and 88 diabetic patients. Figure 1 (A) Blood biochemical analysis showed that the fasting glucose level of diabetic patients was significantly higher than that of normal people, regardless of male or female (p<0.001); Figure 1 (B) Blood biochemical analysis showed that there was no significant difference in serum high-density lipoprotein cholesterol (HDL-C) levels between diabetic patients and normal subjects, regardless of male or female. Figure 1 (C) Blood biochemical analysis showed that there was no significant difference in serum low-density lipoprotein cholesterol (LDL-C) levels between diabetic patients and normal subjects, regardless of male or female. Figure 1 (D) Blood biochemical analysis showed that there was no significant difference in serum triglyceride (TG) levels between diabetic and normal people, regardless of male or female.
[0046] 2. The significant reduction in muscle mass in diabetic people is a typical manifestation of diabetic muscle atrophy
[0047] Diabetic muscle atrophy is a common complication in elderly patients with diabetes. Its main symptoms include muscle weakness, muscle atrophy, pain and weight loss, which often affect the muscles of the thighs and buttocks, making it difficult for patients to walk. Among them, the reduction of muscle mass is a typical manifestation of diabetic muscle atrophy. The results of the physical analysis of the population recruited this time showed that according to the correction standards of the three muscle indexes, the muscle mass of diabetic patients, both men and women, was significantly lower than that of normal people, with the highest reduction rate reaching 30%. This shows that muscle atrophy and reduction in diabetic patients is a fairly common phenomenon and should be paid attention to. Figure 2 As shown in the figure, 333 recruited people (male, 92 normal cases, 74 diabetic cases; female, 79 normal cases, 88 diabetic cases) were all subjected to human body composition analysis (DBA-510, Donghuayuan human body composition analyzer), and the limb muscle mass (ASM) was corrected in three categories according to international standards. (A) Muscle index correction by height squared (ASM / height 2), the analysis showed that the muscle index of diabetic patients was significantly lower than that of normal people, regardless of male or female (p<0.001); (B) the muscle index was corrected by BMI (weight / height squared) (ASM / BMI), and the analysis showed that the muscle index of diabetic patients was significantly lower than that of normal people, regardless of male or female (p<0.001); (C) the muscle index was corrected by body weight (ASM / bodyweight), and the analysis showed that the muscle index of diabetic patients was significantly lower than that of normal people, regardless of male or female (p<0.001).
[0048] 3. Serum IGFBP3 protein levels in diabetic patients are significantly increased
[0049] IGFBP3 is a secretory protein that circulates in the blood. Its main function is believed to be to bind to IGF-1 protein (insulin-like growth factor-1) in the blood circulation, protecting IGF-1 from rapid degradation so that it can stably reach target cells and activate downstream Akt and other signaling pathways by binding to IGF-1R (IGF-1 receptor) to regulate protein synthesis, cell proliferation and survival, etc. This study found in a large-scale sample of diabetic people that the total protein content of IGFBP3 in the blood of diabetic people, regardless of gender, was significantly higher than that of normal people, suggesting that the protein content may have a certain correlation with the pathological characteristics of diabetes, such as Figure 3 As shown, after serum separation from the blood of 333 recruited people (male, 92 normal cases, 74 cases with diabetes; female, 79 normal cases, 88 cases with diabetes), the total amount of IGFBP3 protein in the serum was detected by ELISA. The results showed that the content of IGFBP3 protein in the serum of diabetic patients was significantly higher than that of normal people, regardless of male or female (p<0.001).
[0050] 4. The serum IGFBP3 protein content is significantly negatively correlated with human muscle mass
[0051] A one-to-one correlation analysis of the physical fitness analysis results and blood IGFBP3 protein levels of the recruited population found that the IGFBP3 protein content in the blood was significantly correlated with the muscle mass in the human body, and the correction parameters of the three muscle indexes all had the same correlation and significance. The higher the IGFBP3 protein content, the less muscle content, suggesting that the IGFBP3 protein content can be used as a new diagnostic marker for diabetic muscle atrophy, such as Figure 4 As shown, the serum IGFBP3 levels of 333 recruited people were correlated with their respective corrected muscle indices. Figure 4 (A) Serum IGFBP3 content and height square corrected muscle index (ASM / height 2) were analyzed, and the results showed that the two were significantly negatively correlated (r = -0.26, p < 0.001); Figure 4 (B) The correlation analysis between serum IGFBP3 content and BMI-corrected muscle index (ASM / BMI) showed that the two were significantly negatively correlated (r=-0.24, p<0.001); Figure 4 (C) Correlation analysis between serum IGFBP3 content and body weight-corrected muscle index (ASM / body weight) showed a significant negative correlation between the two (r=-0.29, p<0.001).
[0052] Based on the above experimental results, the following applications can be obtained:
[0053] (1) IGFBP3 protein is used as a biomarker for diagnosing diabetic muscular atrophy.
[0054] (2) A substance for detecting the content of IGFBP3 protein in blood, which is used for diagnosing or assisting in diagnosing whether a person to be tested suffers from diabetic amyotrophy;
[0055] A substance for detecting the IGFBP3 protein content in blood is used in screening or assisting in screening whether a person to be tested suffers from diabetic muscular atrophy.
[0056] A substance for detecting the content of IGFBP3 protein in blood, which is used in the preparation of a product for diagnosing or assisting in diagnosing whether a person to be tested suffers from diabetic muscular atrophy;
[0057] A substance for detecting the IGFBP3 protein content in blood is used in the preparation of a product for screening or assisting in screening whether a person to be tested suffers from diabetic muscular atrophy.
[0058] (3) Use of blood IGFBP3 protein as a marker in diagnosing or assisting in diagnosing whether a person suffers from diabetic amyotrophy;
[0059] Blood IGFBP3 protein is used as a marker in screening or auxiliary screening to determine whether a person suffers from diabetic muscular atrophy.
[0060] (4) Prepare a product for diagnosing or assisting in diagnosis, screening or assisting in screening whether a person suffers from diabetic amyotrophy.
[0061] (5) Provide a system for diagnosing or assisting in the diagnosis, screening or assisting in the screening of whether a person has diabetes based on the marker IGFBP3 protein.
[0062] The present invention is not limited to the above embodiments. Any non-essential additions and substitutions made by those skilled in the art based on the technical features of the technical solution of the present invention shall fall within the protection scope of the present invention.
Claims
1. A diagnostic marker for diabetic amyotrophy, It is characterized in that The marker is IGFBP3 protein, which is the total IGFBP3 protein in free or bound form in human blood.
2. Application of a diagnostic marker for diabetic amyotrophy, It is characterized in that IGFBP3 protein is used as a biomarker for diagnosing diabetic amyotrophy.
3. Application of a diagnostic marker for diabetic muscle atrophy, It is characterized in that A substance for detecting the content of IGFBP3 protein in blood, and its use in diagnosing or assisting in diagnosing whether a person to be tested suffers from diabetic amyotrophy; A substance for detecting the IGFBP3 protein content in blood is used in screening or assisting in screening whether a person to be tested suffers from diabetic muscular atrophy.
4. Use of a diabetic amyotrophy diagnostic marker according to claim 3, It is characterized in that Use of a substance for detecting the content of IGFBP3 protein in blood in the preparation of a product for diagnosing or assisting in diagnosing whether a person to be tested suffers from diabetic muscular atrophy; A substance for detecting the IGFBP3 protein content in blood is used in the preparation of a product for screening or assisting in screening whether a person to be tested suffers from diabetic muscular atrophy.
5. Application of a diagnostic marker for diabetic muscle atrophy, It is characterized in that Use of blood IGFBP3 protein as a marker in diagnosing or assisting in diagnosing whether a person to be tested suffers from diabetic amyotrophy; Use of blood IGFBP3 protein as a marker in screening or assisting in screening whether a person to be tested suffers from diabetic amyotrophy; The candidate human being to be tested is a diabetic patient, a suspected diabetic patient, a diabetic high-risk person, or a direct relative of a diabetic patient.
6. Application of a diagnostic marker for diabetic muscle atrophy, It is characterized in that A product for diagnosing or assisting in the diagnosis, screening or assisting in the screening of whether a person to be tested suffers from diabetic amyotrophy is prepared. The product diagnoses or assists in the diagnosis, screening or assists in the screening of whether a person to be tested suffers from diabetic amyotrophy based on the protein content of IGFBP3 in a blood sample.
7. Use of a diabetic amyotrophy diagnostic marker according to claim 6, It is characterized in that The product is a kit; the kit comprises a reagent for specifically detecting the level of IGFBP3 protein; the reagent comprises an antibody, protein and / or polypeptide that specifically binds to the IGFBP3 protein.
8. Use of a diabetic amyotrophy diagnostic marker according to claim 7, It is characterized in that The antibodies, proteins and / or polypeptides are modified with isotopes, horseradish peroxidase, colloidal gold, fluorescent probes, etc., or are unmodified.
9. Application of a diagnostic marker for diabetic muscle atrophy, It is characterized in that A system for diagnosing or assisting in the diagnosis, screening or assisting in the screening of whether a person to be tested has diabetes based on the marker IGFBP3 protein is provided, comprising: An acquisition device is used to obtain the IGFBP3 protein content in a biological sample; the biological sample comes from the blood of a person to be tested; The judging device is connected to or wirelessly connected to the obtaining device, and is used for diagnosing or assisting in diagnosis, screening or assisting in screening whether the person to be tested suffers from diabetic amyotrophy based on the IGFBP3 protein content in the biological sample.
10. Use of a diabetic amyotrophy diagnostic marker according to claim 9, It is characterized in that The IGFBP3 protein content in the biological sample is higher than that in a normal sample, which indicates that the biological sample suffers from diabetic amyotrophy; the biological sample is blood from a person to be tested.
Citation Information
Cited By
Use of igfbp3 protein as intervention target for diabetic amyotrophy and use of NBI-31772 in preparation of drug for ameliorating diabetic amyotrophy
WO2026031471A1
